Skip to main content
Premium Trial:

Request an Annual Quote

Talis Biomedical Q1 Revenues Drop 54 Percent on Lower Grant Funding

NEW YORK – Talis Biomedical reported after the close of the market on Tuesday that its first quarter revenues decreased 54 percent year over year due to a drop in grant funding.

For the three months ended March 31, the company posted revenues of $3.2 million compared to $7.0 million in Q1 of 2021.

In Q1, the company booked $2.3 million in product revenues, driven by antigen testing sales. It also reported $874,000 in grant revenue, down more than eightfold from $7.0 million in the prior-year quarter when it booked revenues associated with meeting National Institutes of Health's Rapid Acceleration of Diagnostics, or RADx, program milestones.

In March, the point-of-care testing firm announced it was delaying the beta-phase rollout of its Talis One molecular diagnostic system, which had been planned for the first quarter, prompting investment bank BTIG to downgrade the firm's shares from a Neutral to a Sell rating.

However, in a statement on Tuesday, Talis Biomedical CEO Rob Kelley said "I am encouraged by the progress our team has made over the last 60 days toward validation of manufacturing scale-up for our Talis One COVID-19 Test System. With our continued focus on execution and cash preservation, we believe we are on the right path to deliver on our 2022 business objectives."

The Menlo Park, California-based firm also noted that in Q1 it completed the first release of its Sia Dx cloud-based software on the Talis One System.

Talis BioMedical's net loss in the recently completed quarter narrowed to $33.1 million, or $1.25 per share, compared to a net loss of $60.5 million, or $4.61 per share, in Q1 2021.

Its R&D costs dropped 66 percent year over year to $20.7 million from $60.2 million, while its SG&A costs rose 63 percent year over year to $11.9 million from $7.3 million.

At the end of Q1, the firm had cash and cash equivalents of $187.6 million.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.